Cargando...
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia (CML). Imatinib produces acceptable responses in ~ 60% of patients; with ~20% discontinuing therapy due to intolerance and ~20% developing drug resistance. The advent of newer TKIs...
Guardado en:
| Publicado en: | Cancer J |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4742366/ https://ncbi.nlm.nih.gov/pubmed/26841016 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000165 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|